Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chien, Wei Wen ^a   Le Beux, Céline ^a   Rachinel, Nicolas ^a   Julien, Michel ^b   Lacroix, Claire Emmanuelle ^a   Allas, Soraya ^b   Sahakian, Pierre ^b   Cornut Thibaut, Aurélie ^a   Lionnard, Loïc ^a   Kucharczak, Jérôme ^a   Aouacheria, Abdel ^a   Abribat, Thierry ^b   Salles, Gilles ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b Alizeé Pharma   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; ASPARAGINASE; ASPARTATE AMMONIA LIGASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIPROTEIN COMPLEX; PROTEIN KINASE R; TARGET OF RAPAMYCIN KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; LYMPHOMA; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASPARAGINASE; ASPARTATE-AMMONIA LIGASE; CELL LINE, TUMOR; EIF-2 KINASE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPROTEIN COMPLEXES; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84952939515     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08068     Document Type: Article

References (49)

1. Pieters, R. et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117, 238-249 (2011).
2. Avramis, V. I. Asparaginases: a successful class of drugs against leukemias and lymphomas. J Pediatr Hematol Oncol 33, 573-579 (2011).
3. Yong, W. et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. International journal of hematology 78, 163-167 (2003).
4. Yamaguchi, M. et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer science 99, 1016-1020, doi:10.1111/j.1349-7006.2008.00768.x (2008).
5. Jaccard, A. et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 20, 110-116, doi:10.1093/annonc/mdn542 (2009).
6. Asselin, B. L. et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 49, 4363-4368 (1989).
7. Avramis, V. I. & Tiwari, P. N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1, 241-254 (2006).
8. Haskell, C. M. & Canellos, G. P. l-asparaginase resistance in human leukemia - asparagine synthetase. Biochem Pharmacol 18, 2578-2580 (1969).
9. Hutson, R. G. et al. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. The American journal of physiology 272, C1691-1699 (1997).
10. Richards, N. G. & Kilberg, M. S. Asparagine synthetase chemotherapy. Annu Rev Biochem 75, 629-654 (2006).
11. Aslanian, A.M., Fletcher, B. S. & Kilberg, M. S. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J 357, 321-328 (2001).
12. Panosyan, E. H. et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 24, 1121-1125 (2004).
13. Rotoli, B. M. et al. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem 15, 281-292 (2005).
14. Tardito, S. et al. The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 60, 751-758 (2007).
15. Offman,M. N. et al. Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 117, 1614-1621, doi:10.1182/blood-2010-07-298422 (2011).
16. Andrulis, I. L., Argonza, R. & Cairney, A. E. Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin. Somatic cell and molecular genetics 16, 59-65 (1990).
17. Aslanian, A. M. & Kilberg, M. S. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J 358, 59-67 (2001).
18. Avramis, V. I. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res 32, 2423-2437 (2012).
19. Gutierrez, J. A. et al. An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line. Chem Biol 13, 1339-1347 (2006).
20. Li, B. S. et al. The downregulation of asparagine synthetase expression can increase the sensitivity of cells resistant to l-asparaginase. Leukemia 20, 2199-2201, doi: 10.1038/sj.leu.2404423 (2006).
21. Ikeuchi, H. et al. A sulfoximine-based inhibitor of human asparagine synthetase kills L-asparaginase-resistant leukemia cells. Bioorganic & medicinal chemistry 20, 5915-5927, doi:10.1016/j.bmc.2012.07.047 (2012).
22. Ramirez, M. et al. Mutations activating the yeast eIF-2 alpha kinase GCN2: isolation of alleles altering the domain related to histidyl-tRNA synthetases. Molecular and cellular biology 12, 5801-5815 (1992).
23. Harding, H. P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6, 1099-1108 (2000).
24. Harding, H. P. et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11, 619-633 (2003).
25. Ye, J. et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. Embo J 29, 2082-2096, doi: 10.1038/emboj.2010.81 (2010).
26. Balasubramanian, M. N., Butterworth, E. A. & Kilberg, M. S. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. American journal of physiology. Endocrinology andmetabolism 304, E789-799, doi:10.1152/ajpendo.00015.2013 (2013).
27. Gallinetti, J., Harputlugil, E. & Mitchell, J. R. Amino acid sensing in dietaryrestriction-mediated longevity: roles of signal-transducing kinases GCN2 and TOR. Biochem J 449, 1-10, doi:10.1042/BJ20121098 (2013).
28. Thiaville, M. M. et al. MEK signaling is required for phosphorylation of eIF2alpha following amino acid limitation of HepG2 human hepatoma cells. J Biol Chem 283, 10848-10857, doi:10.1074/jbc.M708320200 (2008).
29. Nobukuni, T. et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 102, 14238-14243 (2005).
30. Reiling, J. H. & Sabatini, D. M. Stress and mTORture signaling. Oncogene 25, 6373-6383, doi:10.1038/sj.onc.1209889 (2006).
31. Proud, C. G. Amino acids and mTOR signalling in anabolic function. Biochem Soc Trans 35, 1187-1190, doi:10.1042/BST0351187 (2007).
32. Yamaguchi, S. et al. ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell metabolism 7, 269-276, doi:10.1016/j.cmet.2008.01.008 (2008).
33. Whitney, M. L., Jefferson, L. S. & Kimball, S. R. ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochemical and biophysical research communications 379, 451-455, doi:10.1016/j.bbrc.2008.12.079 (2009).
34. Bunpo, P. et al. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J Biol Chem 284, 32742-32749, doi:10.1074/jbc.M109.047910 (2009).
35. Stams, W. A. et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)1pediatric ALL. Blood 101, 2743-2747, doi:10.1182/blood-2002-08-2446 (2003).
36. Fine, B. M., Kaspers, G. J., Ho, M., Loonen, A. H. & Boxer, L. M. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 65, 291-299 (2005).
37. Hermanova, I., Zaliova, M., Trka, J. & Starkova, J. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase. Experimental hematology 40, 657-665, doi:10.1016/j.exphem.2012.04.005 (2012).
38. Stams, W. A. et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 105, 4223-4225 (2005).
39. Holleman, A. et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351, 533-542 (2004).
40. Chien, W. W. et al. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Investigational new drugs doi:10.1007/s10637-014-0102-9 (2014).
41. Valero, J. G. et al. micro-Calpain conversion of antiapoptotic Bfl-1 (BCL2A1) into a prodeath factor reveals two distinct alpha-helices inducing mitochondriamediated apoptosis. PloS one 7, e38620, doi:10.1371/journal.pone.0038620 (2012).
42. Ren, Y., Roy, S., Ding, Y., Iqbal, J. & Broome, J. D. Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein. Oncogene 23, 3953-3961, doi:10.1038/sj.onc.1207498 (2004).
43. Ding, Y., Li, Z.& Broome, J. D. Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines. Leukemia 19, 420-426, doi:10.1038/sj.leu.2403639 (2005).
44. Yagita, M. et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14, 922-930 (2000).
45. Scian, M. J. et al. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 23, 4430-4443, doi:10.1038/sj.onc.1207553 (2004).
46. Scian, M. J. et al. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 64, 7447-7454, doi:10.1158/0008-5472.CAN-04-1568 (2004).
47. Ando, M. et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130, 860-868 (2005).
48. Suto, H. et al. Suppression of eIF4E expression by L-Asparaginase. Acta Haematol 123, 215-219 (2010).
49. Chien, W. W. et al. Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway. Oncogene 30, 1880-1891, doi:10.1038/onc.2010.570 (2011).